Recombinant Anti-mouse CD3e In Vivo Antibody (500A2)

Anti-mouse CD3e Monoclonal Antibody (Clone: 500A2) | PA007201

$150.00 – $900.00

In vivo Grade Recombinant Anti-mouse CD3e Mouse IgG2a Kappa Monoclonal Antibody (Clone: 500A2). Isotype: Mouse IgG2a kappa. Purity: >95%.

Details & Specifications
References

Catalog No.	PA007201
Product Name	In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 500A2), Mouse IgG2a Kappa
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	cluster of differentiation 3, CD3D, CD3E, CD3G, CD3 epsilon
Summary	The anti-mouse CD3e monoclonal antibody (clone: 500A2) was produced in mammalian cells.
Clone	500A2
Isotype	Mouse IgG2a kappa
Specificity/Sensitivity	The in vivo grade recombinant mouse monoclonal antibody (clone: 500A2) specifically binds to the mouse T cell receptor CD3e.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD3e protein.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The 500A2 antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007201: Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 500A2), Mouse IgG2a Kappa, In vivo Grade

In vivo Grade Recombinant Anti-mouse CD3e Mouse IgG2a Kappa Monoclonal Antibody (Clone: 500A2) was produced in mammalian cells.

References of Anti-mouse CD3e Monoclonal Antibody (Clone: 500A2)

1. CD3e-immunotoxin spares CD62Llo Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3ehi T cells
Xingjie Ren, et al.Front Immunol. 2022 Oct 27;13:1012674. doi: 10.3389/fimmu.2022.1012674. PMID: 36389920; PMCID: PMC9643874
“Selective depletion of T cell subsets remains a major challenge in immunotherapy. This research illustrates that CD3e-targeted immunotoxins can precisely eliminate high-expressing CD3e T cells while leaving regulatory T cells (Tregs) with low CD62L expression unharmed. This targeted strategy provides a highly refined approach for modulating the immune landscape within specific organs.”

2. Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage
Shihyoung Kim, et al.Toxins (Basel). 2022 Jun 15;14(6):410. doi: 10.3390/toxins14060410. PMID: 35740248; PMCID: PMC9220018
“Targeted therapies involving anti-CD3e antibodies and their derived immunotoxins are significant tools for T-cell disorder management. A common complication with these treatments is vascular leak syndrome, which presents safety concerns in clinical applications. This study confirms that the sZAP component of the immunotoxin, rather than the antibody moiety itself, is the primary mediator of vascular toxicity in mouse models.”

3. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Andrea Cossarizza, et al.Eur J Immunol. 2024 May;54(5):e50529. doi: 10.1002/eji.202350529. PMID: 38766904; PMCID: PMC11115438
“Flow cytometry is an essential technology for the analysis and isolation of immune cell populations. These guidelines offer comprehensive recommendations to ensure standardization and high-quality data generation across immunological research. This edition places particular emphasis on technical best practices for surface marker labeling and cellular sorting procedures.”

4. Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma
Jared M. P. Grier, et al.J Immunother Cancer. 2022 Sep;10(9):e004655. doi: 10.1136/jitc-2022-004655. PMID: 36070923; PMCID: PMC9463572
“Regulatory T cells (Tregs) in the tumor microenvironment frequently inhibit effective anti-tumor immune responses. The authors demonstrate that cyclophosphamide treatment significantly reduces tumor-infiltrating Treg populations, thereby enhancing the efficacy of subsequent immune checkpoint blockade. The combination of chemotherapy and anti-PD-1 therapy leads to improved survival outcomes in a murine model of neuroblastoma.”

5. The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function
Sarah E. Marsh, et al.J Exp Med. 2016 Mar 7;213(3):363-75. doi: 10.1084/jem.20150937. PMID: 26903612; PMCID: PMC4780638
“The role of adaptive immunity in neurodegenerative conditions like Alzheimer’s disease has been a subject of intense investigation. This research demonstrates that the adaptive immune system plays a protective role by influencing the behavior and activation state of microglia. Modulation of this immune interaction offers a potential therapeutic avenue to restrain disease pathogenesis in the brain.”

For more technical references or data sheets regarding the Anti-mouse CD3e Monoclonal Antibody (Clone: 500A2) formats, please contact our scientific support team at message@sydlabs.com.